rs75961395
|
|
|
0.810 |
GeneticVariation |
BEFREE |
To study the severity of mutation G85E, located in the first membrane spanning domain of the CFTR gene, we studied the clinical features of 13 Spanish patients with cystic fibrosis (CF) carrying this mutation.
|
8933333 |
1996 |
rs74597325
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A cystic fibrosis patient homozygous for the nonsense mutation R553X.
|
1682496 |
1991 |
rs113993959
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A cystic fibrosis patient with the nonsense mutation G542X and the splice site mutation 1717-1.
|
1757966 |
1991 |
rs113993959
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies.
|
29924856 |
2018 |
rs75527207
|
|
|
0.900 |
GeneticVariation |
BEFREE |
A CFTR potentiator in patients with CF and the G551D mutation.N. Engl.J.Med., 2011.365: 1663-1672.)].
|
22914736 |
2012 |
rs397508316
|
|
|
0.810 |
GeneticVariation |
BEFREE |
A missense mutation, S1235R, was originally reported in a CF patient with a second mutation (G628R) on the same chromosome.
|
11186891 |
2000 |
rs397508599
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A novel G1244R disease causing mutation, leading to a CF phenotype with pancreatic sufficiency but early onset of pulmonary involvement, was detected in the subject with an uncertain diagnosis.
|
16635477 |
2006 |
rs386134230
|
|
|
0.710 |
GeneticVariation |
BEFREE |
A novel mutation of CFTR, c.753_754delAG, was found in a Chinese CF child. c.2909G>A is the most common mutation among Chinese CF patients.
|
31423445 |
2019 |
rs75541969
|
|
|
0.730 |
GeneticVariation |
BEFREE |
A retrospective review of clinical, genetic and biochemical data was performed from individuals homozygous or compound heterozygous for the D1152H mutation followed in 12 Italian cystic fibrosis (CF) centers.
|
25583415 |
2015 |
rs121909005
|
|
|
0.820 |
GeneticVariation |
BEFREE |
A standard OGTT was performed before and after 16weeks of treatment with ivacaftor in 2 sibling patients with CF carrying the S549R gating mutation.
|
26547591 |
2016 |
rs121908757
|
|
|
0.720 |
GeneticVariation |
BEFREE |
A standard OGTT was performed before and after 16weeks of treatment with ivacaftor in 2 sibling patients with CF carrying the S549R gating mutation.
|
26547591 |
2016 |
rs121908755
|
|
|
0.830 |
GeneticVariation |
BEFREE |
A strategy for mutation screening for CF in India must involve testing for p.F508del followed by c.1161delC, c.3849+10 kb C>T and p.S549N.
|
17716958 |
2008 |
rs121908755
|
|
|
0.830 |
GeneticVariation |
BEFREE |
Absence of cystic fibrosis mutations in a large Asian population sample and occurrence of a homozygous S549N mutation in an inbred Pakistani family.
|
7680378 |
1993 |
rs213950
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Absolute linkage between delta F508 and the KM.19-GATT-TUB9-M470V-T854T haplotype (2-2-1-1-1) predicts a relatively recent appearance of delta F508 in Indian CF patients.
|
18782298 |
2009 |
rs75527207
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Additive improvement in G551D CFTR-mediated Cl<sup>-</sup> secretion suggests that resveratrol could enhance ivacaftor therapy in these patients and improve CF-related rhinosinusitis.
|
30152192 |
2019 |
rs75527207
|
|
|
0.900 |
GeneticVariation |
BEFREE |
After several successful clinical trials the potentiator, ivacaftor, is now licenced for use in adults and children (>six years), with CF bearing the class III G551D mutation and FDA licence was recently expanded to include 8 additional class III mutations.
|
24932877 |
2015 |
rs75527207
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.
|
25769931 |
2016 |
rs74571530
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Although frequencies of F508C did not vary significantly between 850 individuals undergoing cystic fibrosis</span> carrier screening and those submitted for diagnostic testing on suspicion of cystic fibrosis, the frequency of F508C in the congenital bilateral absence of the vas deferens population was significantly higher than expected (chi2 = 6.95, corrected P = 0.0486).
|
19092444 |
2008 |
rs75527207
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Although ivacaftor (VX-770) alone and ivacaftor in combination with lumacaftor (VX-809) improve lung function in CF patients with the Gly551Asp and del508Phe mutations, respectively, the effects of these drugs on the function of human CF macrophages are unknown.
|
29146575 |
2018 |
rs75527207
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Although ivacaftor is currently only licensed for use in approximately 5% of the CF population (those who have at least one Gly551Asp mutation), the developmental pathway established by ivacaftor paves the way for other CFTR modulators that may benefit many more patients.
|
24039402 |
2013 |
rs397508462
|
|
|
0.730 |
GeneticVariation |
BEFREE |
Although the D979A mutant is very rare, this mutation combination seemed to be responsible for severe CF phenotypes.
|
9550362 |
1998 |
rs368505753
|
|
|
0.820 |
GeneticVariation |
BEFREE |
Although the decline of lung function did not differ from ΔF508 homozygotes, the fact that a greater proportion of P67L heterozygotes live to an older age suggests that lung function is not the primary factor determining CF progression for P67L heterozygote patients.
|
28392015 |
2017 |
rs34911792
|
|
|
0.720 |
GeneticVariation |
BEFREE |
An exhaustive CFTR gene analysis identified a second mutation in cis of p.Ser1235Arg in all CF patients and in 81.8% CBAVD patients.
|
20717170 |
2011 |
rs74597325
|
|
|
0.800 |
GeneticVariation |
BEFREE |
An individual with the CFTR genotype R553X/F508del-R553Q showed the typical symptoms and electrophysiological anomalies of cystic fibrosis in the airways and intestine.
|
19176844 |
2009 |
rs121909044
|
|
|
0.710 |
GeneticVariation |
BEFREE |
An individual with the CFTR genotype R553X/F508del-R553Q showed the typical symptoms and electrophysiological anomalies of cystic fibrosis in the airways and intestine.
|
19176844 |
2009 |